Artificial intelligence news.
Straight from the original announcements.

OncoRes Medical becomes Ziva Surgical as ELORA moves toward commercialization

November 12, 2026, 02:00By the AI News Bites Editorial TeamSource: PR Newswire
OncoRes Medical becomes Ziva Surgical as ELORA moves toward commercialization
Image: PR Newswire

OncoRes Medical has rebranded as Ziva Surgical as it advances the investigational ELORA® System toward commercialization. The Australian tissue intelligence company says the system is designed to give surgeons real-time information about tissue inside the surgical cavity.

Key points
  • OncoRes Medical is now trading as Ziva Surgical.
  • The ELORA® System uses quantitative micro-elastography.
  • The system is designed to map tissue stiffness and microarchitecture during surgery.
  • ELORA® received FDA Breakthrough Device Designation in 2020.
  • The company is initially targeting breast-conserving surgery.

A new identity for a decade of research

Ziva Surgical is the new trading name and visual identity for the Perth-based company formerly known as OncoRes Medical. The company said the change marks a new stage in its work to improve how solid tumor cancers are detected during surgery.

The technology grew from more than a decade of research and engineering in quantitative micro-elastography, or QME. The work was initially undertaken at the University of Western Australia and the Harry Perkins Institute of Medical Research. Ziva Surgical says it has developed that research from a laboratory technique into the ELORA® System.

According to the company, the goal is to give surgeons information beyond what can be determined through sight and touch. Its longer-term vision is to bring real-time tissue intelligence into the operating room.

ELORA is designed to map tissue during surgery

Breast-conserving surgery can leave surgeons needing to decide whether additional tissue should be removed. The company says approximately one in five women undergoing the procedure face a second operation to remove residual cancer.

Surgeons currently rely on sight, touch, specimen imaging and clinical judgment when assessing whether cancerous tissue remains. Ziva Surgical says these methods can leave residual cancer undetected during the original operation.

Powered by QME, ELORA® is designed to translate the surgeon's sense of touch into objective, microscale imaging. The system is intended to provide quantitative maps of tissue stiffness and microarchitecture inside the surgical cavity, helping surgeons decide what to remove and what to preserve.

The company says ELORA® is designed to complement pathology rather than replace it. The system received FDA Breakthrough Device Designation in 2020. Ziva Surgical also says it is supported by an exclusive commercial license and more than 44 granted patents globally, across 10 patent families in key markets.

Clinical development comes before commercialization

Ziva Surgical said it is advancing its clinical development program and preparing for commercialization. CEO Dr. Katharine Giles said the company is approaching significant milestones in its clinical journey, with results from its Australian clinical trial coming soon.

The company is initially focused on breast-conserving surgery, but says its longer-term plans include other solid tumor cancers. These include prostate cancer, where Ziva Surgical says early feasibility studies have shown promising results.

The rebrand does not change the company's stated mission. Ziva Surgical says it wants to give surgeons greater clarity during operations, with the ultimate goal of helping more patients move forward after a single operation. The announcement positions ELORA® as an investigational system moving toward clinical and commercial milestones, rather than as a replacement for existing pathology.

Ziva SurgicalOncoRes MedicalELORAUniversity of Western AustraliaHarry Perkins Institute of Medical Researchhealthcareresearch findings

Related news

Ascletis reports preclinical results for oral and long-acting obesity drugs
ResearchNovember 16, 2026, 10:10

Ascletis reports preclinical results for oral and long-acting obesity drugs

Ascletis Pharma has presented preclinical results for an oral GLP-1R and GIPR combination and a long-acting triple agonist aimed at obesity treatment. The company said…

SAS and Posit Partner on Governed AI for Life Sciences
BusinessNovember 16, 2026, 09:00

SAS and Posit Partner on Governed AI for Life Sciences

SAS and Posit PBC have formed a partnership to give life sciences organizations more flexibility in using SAS and open-source technologies, initially for clinical…

SAS and Posit partner to bring governed open source AI to life sciences
BusinessNovember 16, 2026, 09:00

SAS and Posit partner to bring governed open source AI to life sciences

SAS and Posit PBC are partnering to give life sciences organizations more flexibility to use SAS and open source technologies in regulated clinical development. The…